Search results for "Original Research Article"

showing 10 items of 137 documents

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

2020

Altres ajuts: This work was supported in part by Fundació La Marató de TV3 (201516-10, 201502-30), Societat Catalana de Cardiologia, "la Caixa" Banking Foundation. Altres ajuts: PERIS/SLT002-16-00234 Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' p…

medicine.medical_specialtyAngiotensin receptorEndorphins; Heart failure; Neprilysin; Sacubitril/valsartan; α-Endorphin; γ-Endorphinα‐EndorphinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]HemodynamicsPilot ProjectsHeart failure030204 cardiovascular system & hematologyγ‐EndorphinvalsartanSacubitril03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicinemedicineHumansDiseases of the circulatory (Cardiovascular) systemalpha-EndorphinOriginal Research ArticleProspective Studies030212 general & internal medicineSacubitril/valsartanγ-EndorphinAngiotensin II receptor type 1Ejection fractionbusiness.industryα-EndorphinStroke Volumegamma-Endorphinmedicine.diseaseSacubitrilValsartanRC666-701Heart failureCardiologyNeprilysinEndorphinsCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

2021

Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of many cancers as they improve clinical outcomes. However, ICIs have also been associated with the development of immune-related adverse drug reactions (ADRs). Among immune-related ADRs, cardiac immune-related ADRs are rare, but also associated with high mortality rates. Objective The objective of this study was to evaluate the occurrence of cardiac ADRs reported with ICIs in the European spontaneous reporting system. Methods We retrieved individual case safety reports on ICI-induced cardiac ADRs from the website of suspected ADR (www.adrreports.eu) of the European pharmacovigilance database (Eudravigilance).…

medicine.medical_specialtyDurvalumabDrug-Related Side Effects and Adverse ReactionsIpilimumabPembrolizumabToxicology030226 pharmacology & pharmacyPharmacovigilance03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinePharmacovigilancemedicineHumansPharmacology (medical)Original Research Article030212 general & internal medicineMyocardial infarctionImmune Checkpoint InhibitorsPharmacologybusiness.industryOdds ratiomedicine.diseaseIpilimumabNivolumabNivolumabbusinessmedicine.drugDrug Safety
researchProduct

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial

2020

Funding: This work was supported in part by an unrestricted grant from Vifor Pharma and Proyectos de Investigación de la Sección de Insuficiencia Cardiaca 2017 from Sociedad Española de Cardiología. The mechanisms underlying the beneficial effect of ferric carboxymaltose (FCM) in patients with heart failure (HF) and iron deficiency (ID) have not been completely characterized. The Myocardial-IRON trial was a double-blind, randomized trial that evaluated myocardial iron repletion following FCM vs. placebo in 53 patients with HF and ID. In this post hoc analysis, we evaluated whether treatment with FCM was associated with cardiac magnetic resonance changes in left and right ventricular functio…

medicine.medical_specialtyMyocardial ironHeart failureSystolic function030204 cardiovascular system & hematologyPlaceboFERRIC CARBOXYMALTOSElaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOriginal Research ArticlesPost-hoc analysismedicineDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleVentricular systolic functionEjection fractionbusiness.industryIron deficiencymedicine.diseaseFerric carboxymaltoseHeart failureRC666-701CardiologyCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Ankle muscle strength discriminates fallers from non-fallers

2014

International audience; It is well known that center of pressure (CoP) displacement correlates negatively with the maximal isometric torque (MIT) of ankle muscles. This relationship has never been investigated in elderly fallers (EF). The purpose of this study was thus to analyze the relationship between the MIT of ankle muscles and CoP displacement in upright stance in a sample aged between 18 and 90 years old that included EF . The aim was to identify a threshold of torque below which balance is compromised. The MIT of Plantar flexors (PFs) and dorsal flexors (DFs) and CoP were measured in 90 volunteers: 21 healthy young adults (YA) (age: 24.1 +/- 5.0), 12 healthy middle-aged adults (MAA)…

medicine.medical_specialtyPOSTURAL SWAYCognitive NeurosciencePostural instabilityIsometric torquelcsh:RC321-571AGECenter of pressure (terrestrial locomotion)medicineelderly fallersankle jointOriginal Research ArticleOLDER-ADULTSlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBalance (ability)business.industryJOINTagingMuscle weaknessWOMENCOMMUNITYmedicine.anatomical_structurepostural stabilityBALANCEPostural stabilityYOUNGMuscle strengthPhysical therapyRISK-FACTORSmuscle strength[ SCCO ] Cognitive sciencemedicine.symptomAnklebusinessTORQUENeuroscienceFrontiers in Aging Neuroscience
researchProduct

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

2016

ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…

medicine.medical_specialtyPediatricsTuberculosisCost effectivenessBedaquilinelcsh:Business03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSocietal perspectivemedicineOriginal Research Article030212 general & internal medicineResource consumptionSensitivity analysescost-effectivenessDisease treatmenthealth care economics and organizationsbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseNational health serviceMDR tuberculosis030228 respiratory systemchemistryItalyEmergency medicineXDR tuberculosisOriginal ArticleBedaquilinebusinesslcsh:HF5001-6182Journal of Market Access & Health Policy
researchProduct

Acute kidney injury in heart failure: a population study

2020

Abstract Aims The objective of the present study is to assess the prognostic value of acute kidney injury (AKI) in the evolution of patients with heart failure (HF) using real‐world data. Methods and results Patients with a diagnosis of HF and with serial measurements of renal function collected throughout the study period were included. Estimated glomerular filtration rate (GFR) was calculated with the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration). AKI was defined when a sudden drop in creatinine with posterior recovery was recorded. According to the Risk, Injury, Failure, Loss, and End‐Stage Renal Disease (RIFLE) scale, AKI severity was graded in three categories: risk [1.5‐…

medicine.medical_specialtyRenal functionHeart failure030204 cardiovascular system & hematologyRisk of hospitalization03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOriginal Research ArticlesRisk of mortalitymedicineHumansDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleRetrospective StudiesFirst episodeCreatininebusiness.industryIncidence (epidemiology)Hazard ratioAcute kidney injurymedicine.disease3. Good healthAcute kidney injurychemistryRisk of mortalityCreatinineRC666-701CardiologyFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateRenal functionESC Heart Failure
researchProduct

Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.

2021

Aims: We sought to compare the effects of furosemide + hypertonic saline solution (HSS) treatment in patients with acute decompensated heart failure in comparison with furosemide alone and the response in a compensated state after an acute saline load with regard to serum levels of heart failure biomarkers. Methods and results: We enrolled 141 patients with acute decompensated heart failure with reduced ejection fraction admitted to our Internal Medicine ward from March 2017 to November 2019. A total of 73 patients were randomized to treatment with i.v. high-dose furosemide plus HSS, whereas 68 patients were randomized to i.v. high-dose furosemide alone. Patients treated with furosemide plu…

medicine.medical_specialtySettore MED/09 - Medicina InternaAcute decompensated heart failuremedicine.medical_treatmentfurosemide Heart failure HSS BiomarkersGastroenterologyFurosemideInternal medicineOriginal Research ArticlesmedicineDiseases of the circulatory (Cardiovascular) systemHumansOriginal Research ArticleHSSDiureticsSalineHeart FailureSaline Solution HypertonicEjection fractionTroponin Tbusiness.industryTherapeutic effectFurosemideAcute decompensated heart failuremedicine.diseaseHypertonic salineRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugESC heart failure
researchProduct

Activity-dependent endogenous taurine release facilitates excitatory neurotransmission in the neocortical marginal zone of neonatal rats.

2014

In the developing cerebral cortex, the marginal zone (MZ), consisting of early-generated neurons such as Cajal-Retzius cells, plays an important role in cell migration and lamination. There is accumulating evidence of widespread excitatory neurotransmission mediated by γ-aminobutyric acid (GABA) in the MZ. Cajal-Retzius cells express not only GABAA receptors but also α2/β subunits of glycine receptors, and exhibit glycine receptor-mediated depolarization due to high [Cl(-)]i. However, the physiological roles of glycine receptors and their endogenous agonists during neurotransmission in the MZ are yet to be elucidated. To address this question, we performed optical imaging from the MZ using …

medicine.medical_specialtyTaurinemicrodialysisNeurotransmissionBiologylcsh:RC321-571Cellular and Molecular Neurosciencechemistry.chemical_compoundGABAInternal medicinemedicineNKCC1Channel blockerOriginal Research ArticleGlycine receptorGABA Agonistslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryGABAA receptorGlutamate receptorGABAA receptorDepolarizationEndocrinologychemistryExcitatory postsynaptic potentialBiophysicsmarginal zoneglycine receptortaurineNeuroscienceFrontiers in cellular neuroscience
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct